<DOC>
	<DOCNO>NCT01935817</DOCNO>
	<brief_summary>Chronic hepatitis C virologic fibrotic disease , mortality result mainly complication cirrhosis HCC . The investigator ' aim evaluate impact supplementation new pharmaceutical complex silybin-vitamin E-phospholipids patient chronic hepatitis C treat Pegylated-Interferon-Î±2b plus Ribavirin .</brief_summary>
	<brief_title>Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis Patients With Chronic Hepatitis C Treated With Peg-IFN-a RBV</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<criteria>18 year age old , infection HCV treatment pegylated interferon 2 alpha ribavirin liver diseases cancer severe jaundice pulmonary renal chronic disease prostatic disease autoimmune disease diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>